Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

uniQure/CSL’s EtranaDez Could Take Lead Position In Hemophilia B Gene Therapy Market

Dec 09 2021

• By Alaric DeArment

3-D Rendering Red Blood Cells — uniQure and CSL Behring announced positive Phase III data for EtranaDez in hemophilia B • Source: Shutterstock

Related Content

Gene Therapy: AAV Doses Should Not Be Subject To Fixed Upper Limit, US FDA Panel Says

Sep 09 2021

UniQure Needs Longer-Term Data For Hemophilia B Gene Therapy EtranaDez

Jun 22 2021

Relief For UniQure Hemophilia Program Sends Ball To FTC’s Court

Apr 26 2021

Related Companies

uniQure N.V.

CSL Limited

Pfizer Inc.

Spur Therapeutics Limited

Additional Topics

Gene Therapy Business Strategies Research & Development Blood & Coagulation Disorders

More from Gene Therapies

More from Advanced Therapies

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.